As shown in Fig. 1A, CIC-mutated tumor samples in all gliomas exhibited significant increases in mutation rates of oncogenic drivers, including FUBP1, NOTCH1, ARID1A, IDH2, MLH1, TET2, KMT2C, and CDKN1B. In addition, increased rates of 1p19q codeletion, TERT promoter mutations, MGMT promoter methylation, and dMMR/MSI were observed in CIC-mutated samples. This evidence concerns the gene KMT2C and glioma.